electroCore Lifts 2026 Revenue Outlook to Over 30% Growth After Q2 Sales Jump 28%; Targets Positive EBITDA by Q3 2027
ECOR sits 61% above its 52-week low of $4.16.
Summary
electroCore posted Q2 2026 revenue of $9.5 million, a 28% year-over-year increase, and raised its full-year guidance to more than 30% growth. The company also set a target for positive Adjusted EBITDA in Q3 2027, a critical milestone given earlier going-concern concerns.
Key Events · Earnings and Guidance · ECOR
-
Q2 Revenue Up 28% to $9.5M
Net sales rose 28% year-over-year to $9.5 million, propelled by U.S. prescription sales through the VA channel and direct-to-consumer Truvaga. The Quell product line stood out, with revenue surging 700% to $1.3 million.
-
Full-Year Guidance Raised to >30% Growth
Reflecting confidence in the commercial restructuring and VA momentum, management lifted 2026 revenue guidance to greater than 30% annual growth over 2025, up from the prior implied outlook.
-
Positive Adjusted EBITDA Targeted for Q3 2027
For the first time, the company laid out a timeline to profitability, projecting positive Adjusted EBITDA in the third quarter of 2027, backed by cost-saving initiatives and scaling revenue.
-
Cash Position of $10.0M at Quarter-End
Cash, equivalents, and marketable securities stood at $10.0 million on June 30, 2026, down from $11.6 million at year-end 2025. Additional capital will likely be needed before the company reaches breakeven.
Analysis · ECOR · Industrial Applications And Services
A strong second quarter saw revenue climb 28% to $9.5 million, fueled by VA prescription sales and accelerating Quell adoption. In response, management raised the full-year 2026 growth target to more than 30% and, for the first time, committed to reaching positive Adjusted EBITDA by the third quarter of 2027. This marks a decisive pivot from the going-concern warnings that shadowed recent filings — the upgraded outlook and commercial restructuring now chart a credible path to breakeven, even though cash remains tight at $10 million. The market will have to balance the growth trajectory against the likely need for additional capital before profitability arrives.
At the time of this filing, ECOR was trading at $6.70 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $60.4M. The 52-week trading range was $4.16 to $10.50. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.